Author

David Christopher Taussig

Institute of Cancer ResearchORCID 0000-0002-6653-7308Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Assay:metabolomics· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Alun Parsons· 1 shared Ana Rio‐MachíniD· 1 shared Caroline Akemi HeckmaniD· 1 shared Csaba BödöriD· 1 shared Farideh Miraki‐Moud· 1 shared Findlay Bewicke‐CopleyiD· 1 shared John G. GribbeniD· 1 shared Jude FitzgibboniD· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Alun Parsons

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes

Pedro Casado, Ana Rio‐Machín, Juho Jalmari Miettinen, Findlay Bewicke‐Copley, Kevin Rouault‐Pierre, Szilvia Krizsán, Alun Parsons, Vinothini Rajeeve, Farideh Miraki‐Moud, David Christopher Taussig, Csaba Bödör, John G. Gribben, Caroline Akemi Heckman, Jude Fitzgibbon, Pedro R. Cutillas

The paper identifies two distinct subgroups of KMT2A-rearranged AML using phosphoproteomics and shows different drug response profiles.

Signal Transduction and Targeted Therapy · Feb 26, 2023Peer-reviewedMolecular Biology